Neurocrine Biosciences has begun a Phase 1 clinical trial of NBIP‑2118, a corticotropin‑releasing factor type 2 (CRF2) peptide agonist designed to treat obesity. The study will evaluate safety and tolerability of once‑weekly subcutaneous doses in healthy‑weight, overweight, and obese adults, with initial data expected in 2027.
NBIP‑2118 represents a differentiated approach to weight loss, aiming to preserve or increase lean mass while reducing fat mass—a limitation of many current obesity drugs. The program could be deployed as a standalone therapy or combined with other mechanisms, such as incretin‑based agents, and complements Neurocrine’s triple‑agonist candidate NBIP‑1968.
The launch of this trial marks a strategic expansion beyond Neurocrine’s core neurological and endocrine portfolio. By entering the obesity market, the company seeks to tap a large unmet need and diversify revenue streams, especially as it pursues a $2.9 billion acquisition of Soleno Therapeutics for Prader‑Willi syndrome. The new study underscores the firm’s commitment to leveraging its CRF biology expertise in metabolic disease.
Neurocrine’s financial health supports this initiative: the company reported a Q4 2025 earnings per share of $1.88, slightly below consensus, and revenue of $805.5 million, just above expectations. With a current ratio of 3.39 and operating profits of $4.67 per share over the past year, the firm has the liquidity to fund early‑stage development while maintaining a robust pipeline.
Chief Medical Officer Dr. Sanjay Keswani highlighted the potential of CRF2 agonism to address lean‑mass loss, stating, “CRF2 agonism is a promising and differentiated mechanism with the potential to address key limitations of existing therapies, including the loss of lean mass during weight reduction.” This commentary signals confidence in the scientific rationale and the strategic fit of NBIP‑2118 within Neurocrine’s broader obesity strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.